Insulet Corporation (PODD) Q2 Revenue Surges 32.9% to $649M, Raises Full-Year Guidance

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Insulet Corporation is one of them.

Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin pump technology, offering innovative diabetes management solutions through its Omnipod Insulin Management System. The flagship Omnipod 5 Automated Insulin Delivery System integrates with continuous glucose monitors to deliver automated, needle-free insulin dosing for type 1 and type 2 diabetes patients, controlled via smartphone or Omnipod controller.

In Q2 2025, Insulet Corporation (NASDAQ:PODD) reported $649.1 million in revenue, up 32.9% year-over-year, driven by strong customer adoption in the U.S. and international markets. The Omnipod product line generated $639 million, with gross margins of 69.7% and operating income of $121.1 million. Net income reached $22.5 million, or $0.32 per share, further cementing PODD’s reputation among the best healthcare stocks. Following this performance, the corporation raised its full-year revenue growth guidance to 24–27% and adjusted operating margin guidance to 17–17.5%.

PODD also strengthened its brand identity through a partnership with Pantone®, launching Omnipod Mango, a vibrant new color celebrating the diabetes community. Insulet Corporation (NASDAQ:PODD) continues expanding Omnipod 5 compatibility with multiple continuous glucose monitors and advancing international adoption, including in Europe, where Omnipod 5 is now the first automated insulin delivery system prescribed for new users.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.